Also found in: Wikipedia.


a topical antineoplastic used in the treatment of AIDS-related cutaneous Kaposi's sarcoma.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



Pharmacologic class: Second-generation retinoid

Therapeutic class: Topical antineoplastic

Pregnancy risk category D


Binds to and activates intracellular retinoid receptor subtypes, regulating expression of genes that control cellular differentiation and proliferation


Topical gel: 0.1%

Indications and dosages

Treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma

Adults: Apply to lesions b.i.d., gradually increasing to t.i.d. or q.i.d. according to individual lesion tolerance


• Hypersensitivity to retinoids or other drug components


Use cautiously in:

• photosensitivity

• concomitant use of insecticides containing diethyltoluamide (DEET)

• elderly patients

• pregnant or breastfeeding patients

• children.


• Apply generous amount of gel to affected area. Let it dry for 3 to 5 minutes before covering with clothing.

Adverse reactions

CNS: paresthesia

Skin: rash, pruritus, exfoliative dermatitis, skin disorder at application site (such as abrasion, burning, blisters, excoriation, scab, cracking, crusting, drainage, eschar, fissure, oozing, peeling, redness, or swelling), edema

Other: pain, increased sensitivity to sunlight or sun lamps


Drug-behaviors. DEET-containing insect repellents: increased adverse reactions to DEET

Patient monitoring

• Monitor patient for serious adverse effects, especially burns caused by exposure to sunlight or sun lamps.

Patient teaching

• Instruct patient to apply generous amount of gel to affected skin area and let dry for 3 to 5 minutes before covering area with clothing.

• Caution patient to avoid applying gel to mucous membranes or to normal skin surrounding lesions.

Inform patient that drug increases sensitivity to sunlight and that exposure to sunlight or sun lamps (even through window glass or on a cloudy day) may cause serious burn of treated areas. Caution him to avoid such exposure.

• Tell patient to avoid insect repellents containing DEET during therapy.

• Emphasize importance of keeping all medical appointments so prescriber can check progress and monitor for unwanted drug effects.

• Advise females of childbearing potential to avoid becoming pregnant while using this drug.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
Mentioned in ?
References in periodicals archive ?
On April 1, 2019, announced the acquisition of the global rights to two established medicines, Salagen tablets (pilocarpine hydrochloride) (excluding Japan) and Panretin gel (alitretinoin), from Eisai Inc.
Pharmaceutical company ADVANZ PHARMA Corp (TSX:ADVZ) revealed on Monday the completion of the acquisition of the global rights to two established medicines, Salagen (pilocarpine hydrochloride) and Panretin (alitretinoin), from Eisai Inc.
Hurley Treatment Therapies by category stage modalities I Topical Antibiotics agents Clindamycin Gentamicin Dapsone Tetracyclines Clindamycin + rifampicin Resorcinol Systemic Antibiotics agents Rifampicin + moxifloxacin + metronidazole Ertapenem Meropenem Ceftriaxone Anti-androgens Ethinylestradiol Cyproterone acetate Finasteride Spironolactone Biguanides Metformin Surgical/ Surgical Laser Deroofing procedure Laser Nd:YAG C[O.sub.2] laser II-III (*) Systemic Biologics agents Etanercept Infliximab Adalimumab Ustekinumab Retinoids Acitretin Alitretinoin Immunosuppressants Methotrexate Cyclosporine Colchicine Surgical Wide radical excision (*) Includes Stage l treatment modalities
The first-generation retinoids are the naturally occurring nonaromatic retinoids, including retinol, retinal, isotretinoin (13-cis RA), tretinoin (atRA), and alitretinoin (9-cis RA).
It is testing the tablet treatment Alitretinoin, which works by reducing skin cell turnover, with a therapy where the hands are exposed to ultraviolet light after they've been soaked in a special solution.
It is testing the tablet treatment Alitretinoin. It works by reducing skin cell turnover, with a therapy where the hands are exposed to ultraviolet light after they've been soaked in a special solution.
Other treatments include local destruction (cryotherapy), topical alitretinoin (9-cis-retinoic acid), intralesional interferon or vinblastine, superficial radiotherapy, liposomal doxorubicin, daunorubicin, or paclitaxel.
(59) Alitretinoin gel 0.1% was also effective in local control of the lesions of Kaposi's sarcoma in a prospective multicenter randomized trial in which the substance was used two times a day for 12 weeks; overall response rate was 37%.
Other local therapies used to manage bulky lesions or for cosmesis include external beam radiation, laser therapy, cryotherapy, photodynamic therapy, topical alitretinoin gel, and intralesional vinblastine.
Local therapies include alitretinoin gel, intralesional chemotherapy, radiotherapy with less than 20Gy, laser and cryotherapy.